Journal of cosmetic dermatology · 2022
Adjunctive treatment for acne vulgaris by tranexamic acid.
Рандомизированное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Charoenwattanayothin Anshittha, Saiwichai Tawee, Chaichalotornkul Sirintip
Аннотация
BACKGROUND: Acne is a chronic, inflammatory skin disorder of pilosebaceous units. Tranexamic acid (TXA) acts as a plasmin inhibitor to reduce blood loss and is also used to treat rosacea due to its anti-inflammatory effects. Some parts of the pathogenesis of rosacea are similar to inflammatory acne.
OBJECTIVES: The study aimed to evaluate the efficacy of 10% TXA serum in treating acne and its adverse effects.
METHODS: A randomized, double-blind, placebo-controlled, split-face study was performed on 18 mild-to-moderate acne patients. Patients applied 10% TXA serum on one side of the face and placebo on another side twice daily for 8 weeks. Acne lesion counts and adverse effects were evaluated every 2 weeks.
RESULTS: Significant differences in total inflammatory acne counts were observed between TXA and placebo since Week 4 (p = 0.008). TXA mainly reduced papules and pustules, as papule counts significantly decreased since the 8th week (p = 0.046) and pustule counts significantly reduced since Week 8 (p = 0.033). Moreover, physicians also found that TXA serum reduced the redness of the skin, corresponding with the imaging from VISIA® Skin Analysis. The anti-inflammatory effect of TXA resulted in less PIE and PIH. Adverse effects, including erythema and scaling, were treated by applying any moisturizing cream.
CONCLUSION: Topical 10% TXA can reduce inflammatory acne effectively. Adverse effects were minor and treat easily.
OBJECTIVES: The study aimed to evaluate the efficacy of 10% TXA serum in treating acne and its adverse effects.
METHODS: A randomized, double-blind, placebo-controlled, split-face study was performed on 18 mild-to-moderate acne patients. Patients applied 10% TXA serum on one side of the face and placebo on another side twice daily for 8 weeks. Acne lesion counts and adverse effects were evaluated every 2 weeks.
RESULTS: Significant differences in total inflammatory acne counts were observed between TXA and placebo since Week 4 (p = 0.008). TXA mainly reduced papules and pustules, as papule counts significantly decreased since the 8th week (p = 0.046) and pustule counts significantly reduced since Week 8 (p = 0.033). Moreover, physicians also found that TXA serum reduced the redness of the skin, corresponding with the imaging from VISIA® Skin Analysis. The anti-inflammatory effect of TXA resulted in less PIE and PIH. Adverse effects, including erythema and scaling, were treated by applying any moisturizing cream.
CONCLUSION: Topical 10% TXA can reduce inflammatory acne effectively. Adverse effects were minor and treat easily.